Estradiol transdermal

Estradiol transdermal

Alora, Climara, Minivelle, Menostar, Vivelle-DOT

Estradiol transdermal drug class

estrogen

Estradiol transdermal dosage form

Transdermal Patch, Once Weekly or Twice Weekly

Estradiol transdermal ON label indication

1. Abnormal vasomotor function or atrophic vagina or vulva (moderate-severe), menopause

2. Postmenopausal osteoporosis, prophylaxis

3. Decreased estrogen level, secondary to hypogonadism, castration, or primary ovarian failure

Estradiol transdermal OFF label indication

Hormone therapy for transgender females (male-to-female), monotherapy or combination therapy

Estradiol transdermal MOA

Estradiol (17β-estradiol; E2) is the most potent of the naturally occurring estrogens and the major estrogen secreted during the reproductive years. Estradiol and other estrogens produce characteristic effects on specific tissues (such as breast), cause proliferation of vaginal and uterine mucosa, increase calcium deposition in bone, and accelerate epiphyseal closure after initial growth stimulation.

Estradiol transdermal box warning

Should not be used to decrease risk of CV disease, breast cancer, or dementia; increased risk of endometrial cancer; secondary exposure risk (transdermal solution)

Estradiol (transdermal) contraindication

Hypersensitivity to estradiol; history of thromboembolic disorders, breast cancer, any estrogen-dependent neoplasm, known or suspected pregnancy, abnormal uterine bleeding not evaluated by provider

Estradiol transdermal pregnancy/breastfeeding

Contraindicated/Compatible

Estradiol transdermal adverse effects

1. Edema

2. application site irritation